Semaglutide
A long-acting GLP-1 receptor agonist studied for glycemic control, weight management, and cardiovascular outcomes in metabolic research.
Molecular Structure
Amino Acid Sequence
Molecular Formula
Molecular Weight
Half-Life
CAS Number
What is Semaglutide?
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1 (GLP-1), engineered for prolonged plasma half-life and resistance to enzymatic degradation. It was developed by Novo Nordisk and shares approximately 94% sequence homology with native human GLP-1, with two key structural modifications: substitution of alanine at position 2 with alpha-aminoisobutyric acid (Aib) to resist DPP-4 cleavage, and attachment of a C18 fatty diacid chain via a spacer at lysine position 20 to enable reversible albumin binding.
Semaglutide is among the most extensively studied peptides in modern metabolic research. The published clinical literature includes large randomized controlled trials examining effects on glycemic control, body weight, cardiovascular outcomes, and kidney function. The SUSTAIN, STEP, SELECT, and FLOW trial programs have produced substantial evidence on the molecule’s pharmacology and outcomes across diverse populations. The compound is approved by major regulators including the FDA and EMA for specific clinical indications.
Mechanism of action
Semaglutide’s mechanisms of action have been investigated across multiple pathways:
- GLP-1 receptor agonism: The peptide acts as a selective agonist at the GLP-1 receptor, a class B G-protein-coupled receptor expressed on pancreatic beta cells, central nervous system regions, and gastrointestinal tissue.
- Glucose-dependent insulin secretion: Research has shown stimulation of insulin release from pancreatic beta cells in a glucose-dependent manner, reducing the risk of hypoglycemia relative to non-selective insulinotropic agents.
- Glucagon suppression: Studies have documented suppression of inappropriate alpha-cell glucagon secretion under hyperglycemic conditions.
- Delayed gastric emptying: Research models suggest activation of vagal pathways slows gastric emptying, contributing to reduced postprandial glucose excursions and prolonged satiety.
- Central appetite regulation: The peptide reaches hypothalamic arcuate nucleus and brainstem GLP-1 receptors, with studies linking this central action to reductions in food intake and reward-driven eating behaviors.
- DPP-4 resistance via Aib substitution: The alpha-aminoisobutyric acid residue at position 2 confers resistance to dipeptidyl peptidase-4 cleavage, extending plasma half-life substantially compared to native GLP-1.
These pathways are characterized in both preclinical models and human clinical research.
Research applications
Semaglutide has been investigated across several research domains, with the most active areas including:
- Type 2 diabetes mellitus: The SUSTAIN clinical trial program demonstrated reductions in HbA1c (typically 1.5-1.8 percentage points) and modest weight loss across diverse populations on background metformin, sulfonylureas, or insulin.
- Obesity and weight management: The STEP trial program documented mean weight reductions of approximately 15% from baseline at 68 weeks with 2.4 mg weekly dosing, substantially exceeding previous pharmacological weight-loss interventions.
- Cardiovascular outcomes research: The SUSTAIN-6 and SELECT trials examined major adverse cardiovascular events in populations with type 2 diabetes and in populations with obesity but without diabetes, respectively, with both demonstrating risk reductions.
- Kidney outcomes research: The FLOW trial examined effects on kidney function and renal endpoints in patients with type 2 diabetes and chronic kidney disease.
- Other metabolic research: Active investigation areas include non-alcoholic steatohepatitis (NASH), Alzheimer’s disease (EVOKE trials), and substance use research.
This compound is intended for laboratory research use only. It has not been approved for human therapeutic use by any regulatory agency.
Storage & reconstitution
In its lyophilized form, semaglutide tolerates ambient temperatures during shipping but should be stored long-term at -20°C, protected from light. Properly stored lyophilized peptide remains stable for 24 months or longer.
Once reconstituted with bacteriostatic water for injection, semaglutide solutions should be stored refrigerated at 2-8°C and used within 28 days. Avoid repeated freeze-thaw cycles, which can degrade peptide structure and reduce activity.
Visual inspection should be performed before each use. The reconstituted solution should be clear and colorless. Reject any solution that appears cloudy, discolored, or contains visible particulate matter.
For step-by-step reconstitution calculations, see our reconstitution calculator.
For laboratory research use only. The compound described on this page is intended exclusively for in vitro research and laboratory experimentation by qualified researchers and is not for human or veterinary use. It is not a drug, food, dietary supplement, or cosmetic, and has not been approved by the FDA, Health Canada, EMA, or any other regulatory authority for the diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition. The information provided on this page is for educational and reference purposes only and does not constitute medical advice. By accessing this content you confirm that you are a qualified researcher purchasing for legitimate laboratory purposes.
